rat anti mouse cd3 primary antibody  (Bio-Rad)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56 bright and CD56 dim NK cells

doi: 10.1007/s00262-026-04306-1

Figure Lengend Snippet: Both CD56 bright and CD56 dim NK cells are most optimally activated by the combination of K562 F cells and cytokines . A Experimental setup to assess the short-term (16 h) effects of individual or combined K562 F and/or cytokine (IL-2 and IL-15) stimulation on NK cell activation by flow cytometry. B Live, single NK cells were gated (Suppl Fig. ) and pooled from all samples and donors ( n = 5). Data were visualized using UMAP dimensionality reduction . The UMAP was generated using all arcsinh-normalized markers listed in C and shows the distribution of cells derived from each stimulation condition. C UMAP visualization of single-cell marker expression, with each cell colored according to expression level; respective markers are indicated above each plot. D–F Density plots of CD69, Granzyme B, and perforin expression in unstimulated and stimulated NK cells of one representative donor. G–I Mean fluorescence intensity (MFI) of CD69, Granzyme B, and perforin expression in CD56 bright and CD56 dim NK cells, determined by manual gating on CD56 expression. J–L The percentage of CD137, IFN-γ, and TNF-α expression in CD56 bright and CD56 dim NK cells, determined by manual gating for each activation marker. Each symbol represents an individual donor ( n = 5). Error bars indicate mean ± SD. Statistical significance was determined using two-way ANOVA followed by Sidak’s multiple comparison test; p values of relevant comparisons are shown (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001)

Article Snippet: CD56 + CD3 − NK cells were isolated from cryopreserved PBMCs using an untouched NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Activation Assay, Flow Cytometry, Generated, Derivative Assay, Marker, Expressing, Fluorescence, Comparison

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56 bright and CD56 dim NK cells

doi: 10.1007/s00262-026-04306-1

Figure Lengend Snippet: Stimulation and expansion of CD56 bright and CD56 dim NK cells result in a homogenous NK cell phenotype that could be distinguished by CD16 expression. A NK cells within the PBMCs ( d = 0) and the NK cell subsets after sorting and expansion with K562 F cells and cytokines ( d = 7) were analyzed by flow cytometry. The viable NK cells (gating in Suppl Fig. from both conditions ( d = 0 and d = 7) of all donors ( n = 3) were combined and visualized using UMAP dimensionality reduction, based on the markers that are shown. The distribution of the cells derived from each NK cell subset on day 0 and day 7 is shown on the UMAP, followed by the normalized arcsinh-transformed marker expression of each cell surface marker, with the respective markers indicated above each plot. BCD Density plots of CD16, NKG2A, and CD94 expression of the NK cell subsets at day 0 and expanded CD56 bright and CD56 dim NK cells at day 7 of one representative donor. E–M The expression levels (MFI) of CD56, NKp46, NKG2D, and CD38, or the percentage of cells expressing CD16, NKG2A/CD94, CD62L, CD27, and CD2 of both CD56 bright and CD56 dim NK cells at day 0 and day 7, determined by manual gating. Each symbol represents a different donor ( n = 3). Error bars represent mean and SD of different donors. Statistical test used was a two-way ANOVA, followed by a Sidak’s multiple comparison test; the p value of each significant comparison is plotted (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0,0001). F Overlay of CD56 bulk NK cells over UMAP dimensional reduction plot. The same living single NK cells as described in panel A were in addition to a bulk NK cell population from the same 3 donors used as input for the UMAP. The bulk NK cells were also cultured with K562 F cells and cytokines for 7 days

Article Snippet: CD56 + CD3 − NK cells were isolated from cryopreserved PBMCs using an untouched NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Expressing, Flow Cytometry, Derivative Assay, Transformation Assay, Marker, Comparison, Cell Culture

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56 bright and CD56 dim NK cells

doi: 10.1007/s00262-026-04306-1

Figure Lengend Snippet: CD56 bright NK cells form clusters with K562 F cells more rapidly, leading to accelerated feeder cells clearance. A Representative images from longitudinal live-cell IncuCyte analysis at the indicated timepoints (in hours) showing CD56 bright and CD56 dim NK cells stimulated with GFP+ K562 F cells (green) and cytokines. B K562 F clearance over 7 days ( t = 168 h), presented as the fold change in green calibrated unit (GCU) integrated intensity of the GFP signal (GFP+ K562 F cells) relative to t = 0 ( n = 4 donors). C Fold expansion of CD56 bright and CD56 dim NK cells over 7 days ( t = 168 h), shown as the percentage of area confluence of NK cells (GFP−) relative to K562 F cells (GFP+) ( n = 4 donors). D Fold expansion of CD56 bright , CD56 dim , and CD56 bulk NK cells isolated from healthy donors ( n = 7) after initial stimulation with K562 F cells and cytokines, calculated as the fold change in counted cell numbers at day 7 compared to day 0. E Frequency of Ki-67+ CD56 bright and CD56 dim NK cells in unstimulated NK cells present in cryopreserved PBMC from healthy donors ( n = 7), measured by flow cytometry at day 0. F Fold expansion of CD56 bright and CD56 dim NK cells ( n = 3) following restimulation at day 7 with K562 F cells and cytokines, calculated as the fold change in counted cell numbers at day 14 compared to day 7. Each symbol represents an individual donor ( n = 3). Error bars show mean ± SD. Statistical significance was determined using a paired t test; p values of relevant comparison are indicated (ns = nonsignificant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001)

Article Snippet: CD56 + CD3 − NK cells were isolated from cryopreserved PBMCs using an untouched NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Isolation, Flow Cytometry, Comparison

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56 bright and CD56 dim NK cells

doi: 10.1007/s00262-026-04306-1

Figure Lengend Snippet: CD56 bright and CD56 dim NK cells exhibit similar NK-mediated cytotoxicity, but CD56 dim NK cells remain the principal effector cell for antibody-dependent cellular cytotoxicity. A 16-h flow cytometry-based cytotoxicity assay of 7-day K562 F and cytokine-stimulated sorted CD56 bright and CD56 dim NK cells against the dTomato + , NK-sensitive, HLA-negative cell line K562 ( n = 3 donors) at different E/T ratios. Cytotoxicity was calculated as: Cytotoxicity (%) = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\left(1-\frac{\#\text{ dTomato}+\text{ living target cells after co}-\text{culture }}{\#\text{ dTomato}+\text{ living untreated target cells}}\right)$$\end{document} 1 - # dTomato + living target cells after co - culture # dTomato + living untreated target cells × 100%. B ADCC-mediated flow cytometry-based cytotoxicity assay of 7-day K562 F and cytokine-stimulated CD56 bright and CD56 dim cells against the CD20+ dTomato + B-ALL cell line ALL BV. C Burkitt’s lymphoma cell line Raji at two E/T ratios (1:1 and 1:3) in the presence of 10 or 100 µg/mL rituximab, respectively. Cytotoxicity was calculated as above. Rituximab-mediated cellular cytotoxicity was determined as: % cytotoxicity (tumor cells + RTX)—% cytotoxicity (tumor cells alone). Each symbol represents an individual donor. Error bars represent mean and SD of the donors. Statistical significance was determined using a paired t test, with p values indicated (ns = nonsignificant, * = p < 0.05)

Article Snippet: CD56 + CD3 − NK cells were isolated from cryopreserved PBMCs using an untouched NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Flow Cytometry, Cytotoxicity Assay, Co-Culture Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56 bright and CD56 dim NK cells

doi: 10.1007/s00262-026-04306-1

Figure Lengend Snippet: CD56 bright NK cells are more susceptible to retroviral transduction than CD56 dim NK cells. A Schematic overview of the 14-day production protocol for engineered NK:TCR and NK:CAR cell products derived from FACS-sorted CD56 bright , CD56 dim , and CD56 bulk NK cells. B Transduction efficiency of the indicated retroviral constructs (Suppl Fig. ) measured by flow cytometry at day 7 post-isolation. Percentages of TCR/CD3 + were calculated of total CD8β+ -transduced NK cells, and percentages of CAR+ and tNGFR+ were calculated of total NK cells. Each symbol represents an individual donor ( n = 3–5). Error bars indicate mean ± SD across donors. Statistical significance was assessed using a one-way repeated measurement ANOVA, with p values of each comparison plotted (ns = nonsignificant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). C Representative flow cytometry plots of transduced and subsequently MACS-purified final NK:TCR and NK:CAR products at day 14, derived from FACS-sorted CD56 bright , CD56 dim , and CD56 bulk NK cells

Article Snippet: CD56 + CD3 − NK cells were isolated from cryopreserved PBMCs using an untouched NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Retroviral, Transduction, Derivative Assay, Construct, Flow Cytometry, Isolation, Comparison, Purification

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56 bright and CD56 dim NK cells

doi: 10.1007/s00262-026-04306-1

Figure Lengend Snippet: Both CD56 dim and CD56 bright NK cells mediate CAR- and TCR-specific antitumor cytotoxicity. Sixteen-hour flow cytometry-based cytotoxicity assays using NK:BOB1-TCR, NK:CD19-CAR, and NK:MOCK cell products derived from FACS-sorted CD56 bright and CD56 dim NK cells. A–C NK:BOB1-TCR and NK:MOCK cell subsets were tested against A dTomato + LCL JY (TCR Ag+ ; BOB1 + /HLA-B7 +), LCL HHC (TCR Ag+ ; BOB1 + /HLA-B7+), B LCL IZA (TCR Ag−; BOB1 + /HLA-B7−), and C MM cell line UM9 (TCR Ag+ ; BOB1 + /HLA-B7+) using NK:BOB1-TCR and NK:MOCK cells derived from CD56 bright , CD56 dim , and CD56 bulk NK cells. DE NK:CD19-CAR and NK:MOCK cells derived from CD56 bright , CD56 dim , and CD56 bulk NK cells against D dTomato + LCL IZA (CAR Ag + ; CD19+) and E dTomato + B-ALL cell line ALL BV (CAR Ag+ ; CD19+). Cytotoxicity was calculated as: Cytotoxicity (%) = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\left(1-\frac{\#\text{ dTomato}+\text{ living target cells after co}-\text{culture }}{\#\text{ dTomato}+\text{ living untreated target cells}}\right)$$\end{document} 1 - # dTomato + living target cells after co - culture # dTomato + living untreated target cells × 100%. Each symbol represents an individual donor. Error bars show mean ± SD. Statistical significance was assessed using multiple paired t tests, with p values indicated (ns = nonsignificant, * = p < 0.05)

Article Snippet: CD56 + CD3 − NK cells were isolated from cryopreserved PBMCs using an untouched NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Flow Cytometry, Derivative Assay, Co-Culture Assay

Journal: ImmunoTargets and Therapy

Article Title: Enhancing Anti-CTLA-4 Antibody Delivery to the Brain Using Focused Ultrasound and Microbubbles

doi: 10.2147/ITT.S569804

Figure Lengend Snippet: Co-localisation of CD3 + cells and MHC class II + cells with anti-CTLA-4 antibody . ( A and B ) Immunofluorescence staining of CD3 + cells in long-pulse ultrasound treated brains ( A ) and RaSP-treated brains ( B ) of wild-type mice superimposed with anti-CTLA-4 antibody fluorescence and DAPI (nuclei staining). ( C and D ) Immunofluorescence staining of MHC class II + cells in long-pulse ( C ) or RaSP-treated brains ( D ) of wild-type mice superimposed with anti-CTLA-4 antibody fluorescence and DAPI (nuclei staining).

Article Snippet: T cells were stained using a rat anti-mouse CD3 primary antibody (1:200; clone: KT3, #MCA500G, Bio-Rad, CA, USA) with 1% (w/v) milk powder (Tesco, Hertfordshire, England) dissolved in TBS (#524750-1EA, EMD Millipore Corporation, Burlington, MA, USA) and a secondary Alexa Fluor 488 goat anti-rat IgG H&L secondary antibody (1:400; #ab150157, Abcam, Cambridge, England) with 1% (w/v) milk powder in TBS.

Techniques: Immunofluorescence, Staining, Fluorescence

Journal: ImmunoTargets and Therapy

Article Title: Enhancing Anti-CTLA-4 Antibody Delivery to the Brain Using Focused Ultrasound and Microbubbles

doi: 10.2147/ITT.S569804

Figure Lengend Snippet: CD3 + and MHC class II + invasion in ultrasound-treated brain regions . Immunofluorescence staining shows differences in the invasion of CD3 + ( A – D ) and MHC class II + ( E – H ) cells into the ultrasound-treated brain regions ( A, C, E and G ) compared to control brain regions ( B, D, F and H ) using long-pulse ( A, B, E and F ) and RaSP ( C, D, G and H ) sequences. The total count of CD3 + ( I ) and MHC class II + ( J ) cells was determined in treated brain regions targeted with ultrasound at 0.71 MPa with both long pulse and rapid short-pulse sequences compared to control (untreated) regions. A significant increase in T cells ( I ) and MHC class II + cells ( J ) was observed in ultrasound-treated compared to control brain regions in long-pulse treated brains. Scale bars represent 200 µm. The plot shows mean ± SEM (n= 3); * p-value ≤ 0.05 (0.0021 ( I )) and *** p-value ≤ 0.0001 (0.0001 ( J )).

Article Snippet: T cells were stained using a rat anti-mouse CD3 primary antibody (1:200; clone: KT3, #MCA500G, Bio-Rad, CA, USA) with 1% (w/v) milk powder (Tesco, Hertfordshire, England) dissolved in TBS (#524750-1EA, EMD Millipore Corporation, Burlington, MA, USA) and a secondary Alexa Fluor 488 goat anti-rat IgG H&L secondary antibody (1:400; #ab150157, Abcam, Cambridge, England) with 1% (w/v) milk powder in TBS.

Techniques: Immunofluorescence, Staining, Control

Journal: Biomolecules

Article Title: Human Alpha-1 Antitrypsin Suppresses Melanoma Growth by Promoting Tumor Differentiation and CD8 + T-Cell-Mediated Immunity

doi: 10.3390/biom16010122

Figure Lengend Snippet: Immunohistochemical and immunofluorescent staining of B16F10 tumors from WT and hAAT-TG mice. ( A ) Representative tumor sections from B were stained for Ki-67, apoptosis using TUNEL assay, and CD3 with 3-Amino-9-ethylcarbazole (AEC) staining. Left panels: sections from WT mice. Middle panels: sections from hAAT-TG mice. Right panels: quantification of Ki-67-positive cells, TUNEL-positive area, and number of CD3 + cells. ( B ) Representative tumor sections from B were stained for CD4, CD8, and Foxp3 with Immunofluorescence staining (Green). Left panels: sections from WT mice. Middle panels: sections from hAAT-TG mice. Right panels: quantification of CD4 + cells, CD8 + cells, and Foxp3 + cells. Representative images are shown. Scale bar = 100 μm. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 vs. corresponding tumors in WT mice on the same day.

Article Snippet: Primary antibodies included rabbit anti-mouse Ki-67 (Abcam, Cambridge, MA, USA), rat anti-mouse CD3 (Bio-Rad, Hercules, CA, USA), rat anti-mouse CD8a antibody (ThermoFisher, Waltham, MA, USA), rabbit anti-mouse CD4 (Abcam), and rat anti-mouse Foxp3 (ThermoFisher).

Techniques: Immunohistochemical staining, Staining, TUNEL Assay, Immunofluorescence

Journal: Biomolecules

Article Title: Human Alpha-1 Antitrypsin Suppresses Melanoma Growth by Promoting Tumor Differentiation and CD8 + T-Cell-Mediated Immunity

doi: 10.3390/biom16010122

Figure Lengend Snippet: Tumor growth curves of hAAT-TG mice depleted of CD4 + and/or CD8 + T cells. ( A ) hAAT-TG mice were depleted of CD4 + , CD8 + , or both CD4 + /CD8 + T cells using specific depleting antibodies. Flow cytometric analysis of CD4 and CD8 after CD3-gating of splenocytes 3 days after the depletion in mice treated with IgG control, anti-CD4, anti-CD8, and combination of anti-CD4 and anti-CD8 antibodies. ( B ) hAAT-TG mice were depleted of CD4 + , CD8 + , or both CD4 + /CD8 + T cells using specific depleting antibodies on days −3, 0, and 3 relative to tumor implantation (day 0), followed by weekly doses on days 7, 14, and 21 (red arrows). Tumor growth was monitored for 24 days. Data are represented as mean ± SEM ( n = 4 for mice with IgG control, anti-CD4, and anti-CD8, and n = 2 for mice treated with anti-CD4 and anti-CD8). ** p < 0.01, *** p < 0.001.

Article Snippet: Primary antibodies included rabbit anti-mouse Ki-67 (Abcam, Cambridge, MA, USA), rat anti-mouse CD3 (Bio-Rad, Hercules, CA, USA), rat anti-mouse CD8a antibody (ThermoFisher, Waltham, MA, USA), rabbit anti-mouse CD4 (Abcam), and rat anti-mouse Foxp3 (ThermoFisher).

Techniques: Control, Tumor Implantation